⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28905617 | 1.00 | — | — | |
| SCHEMBL1561 | 0.93 | — | — | |
| SCHEMBL2552774 | 0.93 | — | — | |
| SCHEMBL224443 | 0.86 | — | — | |
| SCHEMBL22092371 | 0.86 | — | — | |
| SCHEMBL25405176 | 0.86 | — | — | |
| SCHEMBL135172 | 0.86 | — | — | |
| SCHEMBL21409672 | 0.86 | — | — | |
| SCHEMBL133773 | 0.86 | — | — | |
| SCHEMBL8829599 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366063-B1 | INHIBITORS OF LYN-ASSOCIATED SIGNAL TRANSDUCTION (LAST) AND THE USE THEREOF IN THE TREATMENT OF PROSTATE CANCER | CHILDRENS MEDICAL CENTER (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080045460-A1 | TREATMENT OF PROSTATE CANCER BY INHIBITING LYN-TYROSINE KINASE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| EP-1366063-A2 | USE OF INHIBITORS OF LYN-ASSOCIATED SIGNAL TRANSDUCTION (LAST) IN THE TREATMENT OF PROSTATE CANCR | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20020151497-A1 | Treatment of prostate cancer by inhibiting Lyn tyrosine kinase | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2002-10-17 | — | — | US | disclosed |
| WO-2002047710-A2 | USE OF INHIBITORS OF LYN-ASSOCIATED SIGNAL TRANSDUCTION (LAST) IN THE TREATMENT OF PROSTATE CANCER | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |